G J Fox1,2, V N Nguyen3, N S Dinh3, L P H Nghiem2, T N A Le3, T A Nguyen2, B H Nguyen3,4, H D Nguyen5, N B Tran2, T L Nguyen2, T N Le2, V H Nguyen2, T L Phan2, K C Nguyen3,6, J Ho1, D C Pham2, W J Britton1,7, J R B M Bestrashniy2, G B Marks2,8. 1. Faculty of Medicine and Health, University of Sydney, Australia. 2. Woolcock Institute of Medical Research, Glebe, New South Wales, Australia. 3. National Lung Hospital, Ba Dinh, Hanoi, Vietnam. 4. Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, Paris, France. 5. Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam. 6. Hanoi Medical University, Hanoi, Vietnam. 7. Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, New South Wales, Australia. 8. South Western Sydney Clinical School, University of New South Wales, Kensington, New South Wales, Australia.
Abstract
BACKGROUND: Tuberculosis is the leading infectious cause of death. Steep reductions in tuberculosis-related mortality are required to realize the World Health Organization's "End Tuberculosis Strategy." However, accurate mortality estimates are lacking in many countries, particularly following discharge from care. This study aimed to establish the mortality rate among patients with pulmonary tuberculosis in Vietnam and to quantify the excess mortality in this population. METHODS: We conducted a prospective cohort study among adult patients treated for smear-positive pulmonary tuberculosis in 70 clinics across Vietnam. People living in the same households were recruited as controls. Participants were re-interviewed and their survival was established at least 2 years after their treatment with an 8-month standardized regimen. The presence of relapse was established by linking identifying data on patients and controls to clinic registries. Verbal autopsies were performed. The cumulative mortality among patients was compared to that among a control population, adjusting for age and gender. RESULTS: We enrolled 10964 patients and 25707 household controls. Among enrolled tuberculosis patients, 9% of patients died within a median follow-up period of 2.9 years: 342 (3.1%) during treatment and 637 (5.8%) after discharge. The standardized mortality ratio was 4.0 (95% confidence interval 3.7-4.2) among patients with tuberculosis, compared to the control population. Tuberculosis was the likely cause of death for 44.7% of these deceased patients. CONCLUSIONS: Patients treated for tuberculosis had a markedly elevated risk of death, particularly in the post-treatment period. Interventions to reduce tuberculosis mortality must enhance the early detection of drug-resistance, improve treatment effectiveness, and address non-communicable diseases.
BACKGROUND:Tuberculosis is the leading infectious cause of death. Steep reductions in tuberculosis-related mortality are required to realize the World Health Organization's "End Tuberculosis Strategy." However, accurate mortality estimates are lacking in many countries, particularly following discharge from care. This study aimed to establish the mortality rate among patients with pulmonary tuberculosis in Vietnam and to quantify the excess mortality in this population. METHODS: We conducted a prospective cohort study among adult patients treated for smear-positive pulmonary tuberculosis in 70 clinics across Vietnam. People living in the same households were recruited as controls. Participants were re-interviewed and their survival was established at least 2 years after their treatment with an 8-month standardized regimen. The presence of relapse was established by linking identifying data on patients and controls to clinic registries. Verbal autopsies were performed. The cumulative mortality among patients was compared to that among a control population, adjusting for age and gender. RESULTS: We enrolled 10964 patients and 25707 household controls. Among enrolled tuberculosispatients, 9% of patients died within a median follow-up period of 2.9 years: 342 (3.1%) during treatment and 637 (5.8%) after discharge. The standardized mortality ratio was 4.0 (95% confidence interval 3.7-4.2) among patients with tuberculosis, compared to the control population. Tuberculosis was the likely cause of death for 44.7% of these deceased patients. CONCLUSIONS:Patients treated for tuberculosis had a markedly elevated risk of death, particularly in the post-treatment period. Interventions to reduce tuberculosismortality must enhance the early detection of drug-resistance, improve treatment effectiveness, and address non-communicable diseases.
Authors: Kavindhran Velen; Viet Nhung Nguyen; Binh Hoa Nguyen; Tho Dang; Hoang Anh Nguyen; Dinh Hoa Vu; Thu Thuong Do; Cuong Pham Duc; Huu Lan Nguyen; Huu Thuong Pham; Ben J Marais; James Johnston; Warwick Britton; Justin Beardsley; Joel Negin; Virginia Wiseman; Guy Barrington Marks; Thu Anh Nguyen; Greg J Fox Journal: BMJ Open Date: 2022-06-22 Impact factor: 3.006
Authors: Serena P Koenig; Ahra Kim; Bryan E Shepherd; Carina Cesar; Valdilea Veloso; Claudia P Cortes; Denis Padgett; Brenda Crabtree-Ramírez; Eduardo Gotuzzo; Catherine C McGowan; Timothy R Sterling; Jean W Pape Journal: Clin Infect Dis Date: 2020-06-24 Impact factor: 9.079
Authors: B W Allwood; M Stolbrink; N Baines; E Louw; D T Wademan; A Lupton-Smith; S Nel; D Maree; S Mpagama; M Osman; F M Marx; G Hoddinott; M Lesosky; J Rylance; K Mortimer Journal: Int J Tuberc Lung Dis Date: 2021-04-01 Impact factor: 2.373
Authors: Max J Hassenstein; Ghazal Aarabi; Peter Ahnert; Heiko Becher; Claus-Werner Franzke; Julia Fricke; Gérard Krause; Stephan Glöckner; Cornelia Gottschick; André Karch; Yvonne Kemmling; Tobias Kerrinnes; Berit Lange; Rafael Mikolajczyk; Alexandra Nieters; Jördis J Ott; Wolfgang Ahrens; Klaus Berger; Claudia Meinke-Franze; Sylvia Gastell; Kathrin Günther; Karin Halina Greiser; Bernd Holleczek; Johannes Horn; Lina Jaeschke; Annika Jagodzinski; Lina Jansen; Carmen Jochem; Karl-Heinz Jöckel; Rudolf Kaaks; Lilian Krist; Oliver Kuß; Susan Langer; Nicole Legath; Michael Leitzmann; Wolfgang Lieb; Markus Loeffler; Nina Mangold; Karin B Michels; Christa Meisinger; Nadia Obi; Tobias Pischon; Tamara Schikowski; Sabine Schipf; Matthias B Schulze; Andreas Stang; Sabina Waniek; Kerstin Wirkner; Stefan N Willich; Stefanie Castell Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2020-04 Impact factor: 1.513
Authors: Yvetot Joseph; Zhiwen Yao; Akanksha Dua; Patrice Severe; Sean E Collins; Heejung Bang; Marc Antoine Jean-Juste; Oksana Ocheretina; Alexandra Apollon; Margaret L McNairy; Kathryn Dupnik; Etienne Cremieux; Anthony Byrne; Jean W Pape; Serena P Koenig Journal: J Int AIDS Soc Date: 2021-07 Impact factor: 5.396
Authors: Otavio T Ranzani; Laura C Rodrigues; Sidney Bombarda; Cátia M Minto; Eliseu A Waldman; Carlos R R Carvalho Journal: Lancet Infect Dis Date: 2019-10-31 Impact factor: 71.421
Authors: Giorgi Kuchukhidze; Davit Baliashvili; Natalia Adamashvili; Ana Kasradze; Russell R Kempker; Matthew J Magee Journal: Open Forum Infect Dis Date: 2021-03-15 Impact factor: 3.835